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INTRODUCTION 
 Human immunodeficiency virus (HIV) infection in humans is 
now pandemic. As of January 2006, the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) and the World Health 
Organization (WHO) estimate that AIDS has killed more than 25 
million people since it was first recognized on December 1, 1981, 
making it one of the most destructive pandemics in recorded history. 
In 2005 alone, between 3.4 and 6.2 million people were newly 
infected and between 2.4 and 3.3 million people with AIDS died, an 
increase from 2004 and the highest number since 1981. Globally, 
between 33.4 and 46 million people currently live with HIV. [1]       
Two-thirds of HIV/AIDS infections in Asia occur in India, with 
an estimated 5.7 million infections (estimated 3.4–9.4 million) (0.9% 
of population, it accounts for 10% of global HIV burden), surpassing 
South Africa's estimated 5.5 million (4.9–6.1 million) (11.9% of 
population) infections, making India the country with the highest 
number of HIV infections in the world. [2]     
HIV/AIDS is no longer just a public health issue in India but 
become one of the most serious socioeconomic and developmental 
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concerns because nearly 89% of reported cases are occurring in 
sexually active and economically productive group of 15 to 44 years.[3]  
Although HIV/AIDS is still largely concentrated in at risk 
populations, data suggests that epidemic is moving beyond these 
groups in some regions and in general population through the bridging 
population. [4] It is also moving from urban to rural areas.[5]    The  
spread of HIV in India has been diverse with much of having a low 
rate of infection and the epidemic being the most extreme in the 
southern half of the country and in the far     north-east. The highest 
HIV prevalence rates are found in Maharastra, Andhra Pradesh, 
Karnataka, Manipur and Nagaland. As of July 2005, all of the 
nationally reported AIDS cases were in Maharastra, Gujarat, 
Tamilnadu, Andhra Pradesh, Manipur, West Bengal. In the southern 
states, infections are mostly due to heterosexual contact while 
infections are mainly found among injecting drug users in Manipur 
and Nagaland. 
HIV infects cells in the immune system and the central nervous 
system. The main type of cell that HIV infects is the T helper 
lymphocyte. These cells play a crucial role in the immune system, by 
coordinating the actions of other immune system cells. A large 
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reduction in the number of T helper cells seriously weakens the 
immune system.  
HIV infects the T helper cell because it has the protein CD4 on 
its surface, which HIV uses to attach itself to the cell before gaining 
entry. This is why the T helper cell is sometimes referred to as a CD4+ 
lymphocyte. Once it has found its way into a cell, HIV produces new 
copies of itself, which can then go on to infect other cells.  
Over time, HIV infection leads to a severe reduction in the 
number of T helper cells available to help fight disease. The process 
usually takes several years. 
Following infection with HIV, the rate of clinical disease 
progression varies enormously between individuals. Many factors 
such as host susceptibility and immune function, [6][7][8] health care and 
co-infections, [9]10][11] as well as factors relating to the viral strain [12][13] 
may affect the rate of clinical disease progression. Symptomatic HIV 
infection is mainly caused by the emergence of opportunistic 
infections and cancers that the immune system would normally 
prevent. These can occur in almost all the body systems. 
HIV infection leads to AIDS and major cause of morbidity and 
mortality of such patients are opportunistic infections. [14]  
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Epidemiology and clinical features differ from country to country. The 
clinical features and opportunistic infections may depend on the 
organisms and the parasites endemic in that country. The diagnosed 
HIV/AIDS cases represent only tip of the iceberg. High index of 
suspicion is necessary for the diagnosis. Hence the present study was 
carried out to elucidate the epidemiological and clinical spectrum of 
HIV disease, among the HIV seropositive patients admitted in 
Coimbatore medical college hospital, Coimbatore.   
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1. To find out common clinical manifestations and various 
complications of HIV disease. 
2.  To determine the frequency of occurrence of opportunistic 
infections in adult HIV/AIDS patients. 
3. To find new clinical manifestations of HIV disease, if any.  
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Human immunodeficiency virus (HIV) is a retrovirus that can 
lead to acquired immunodeficiency syndrome (AIDS, a condition in 
humans in which the immune system begins to fail, leading to life-
threatening opportunistic infections). Previous names for the virus 
include human T-lymphotropic virus-III (HTLV-III), 
lymphadenopathy-associated virus (LAV), or AIDS-associated 
retrovirus (ARV).[15][16] 
HIV primarily infects vital cells in the human immune system 
such as helper T cells (specifically CD4+ T cells), macrophages and 
dendritic cells. 
 HIV infection leads to low levels of CD4+ T cells through three 
main mechanisms: firstly, direct viral killing of infected cells; 
secondly, increased rates of apoptosis in infected cells; and thirdly, 
killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that 
recognize infected cells. 
When CD4+ T cell numbers decline below a critical level, cell-
mediated immunity is lost, and the body becomes progressively more 
susceptible to opportunistic infections. If untreated, eventually most 
HIV-infected individuals develop AIDS (Acquired Immunodeficiency     
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Syndrome) and die; however about one in ten remains healthy for 
many years, with no noticeable symptoms. [17]     
                       Treatment with anti-retrovirals, where available, 
increases the life expectancy of people infected with HIV. It is hoped 
that current and future treatments may allow HIV-infected individuals 
to achieve a life expectancy approaching that of the general public. 
Epidemiology 
AIDS pandemic 
 
 
Prevalence of HIV among adults per country at the end of 2005      15–50%      5–
15%      1–5%      0.5–1.0%      0.1–0.5%      <0.1%      no data 
                        UNAIDS and    the    WHO  estimate   that AIDS 
has killed  more    than   25  million    people     since it  was first  
recognized in 1981,  making  it  one  of  the  most destructive 
pandemics  in  recorded  history.Despite  recent     improved     access 
to     antiretroviral   treatment   and     care          in many regions of  
the world, the AIDS pandemic claimed an estimated,                          
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2.8 million (between 2.4 and 3.3 million) lives in 2005 of which more 
than half a million (570,000) were children.[1] 
Globally, between 33.4 and 46 million people currently live 
with HIV.1] In 2005, between 3.4 and 6.2 million people were newly 
infected and between 2.4 and 3.3 million people with AIDS died, an 
increase from 2004 and the highest number since 1981. 
Classification 
HIV was classified as a member of the genus Lentivirus,[18] part 
of the family of Retroviridae.[19] 
Lentiviruses have many common morphologies and biological 
properties. Many species are infected by lentiviruses, which are 
characteristically responsible for long-duration illnesses with a long 
incubation period.[20] 
Lentiviruses are transmitted as single-stranded, positive-sense, 
enveloped RNA viruses. Upon entry of the target cell, the viral RNA 
genome is converted to double-stranded DNA by a virally encoded 
reverse transcriptase that is present in the virus particle. This viral 
DNA is then integrated into the cellular DNA by a virally encoded 
integrase so that the genome can be transcribed. 
8 
                                                                       
Once the virus has infected the cell, two pathways are possible: 
either the virus becomes latent and the infected cell continues to 
function, or the virus becomes active and replicates, and a large 
number of virus particles are liberated that can then infect other cells. 
Transmission 
Estimated per act risk for acquisition of HIV-1 by exposure route[24] 
Exposure Route  Estimated infections per 10,000 exposures to an infected source 
Blood Transfusion  9,000[25]  
Childbirth 2,500[26] 
Needle-sharing injection drug use 67[27] 
Receptive anal intercourse* 50[28][29] 
Percutaneous needle stick 30[30] 
Receptive penile-vaginal intercourse* 10[28][29][31] 
Insertive anal intercourse* 6.5[28][29] 
Insertive penile-vaginal intercourse* 5[28][29] 
Receptive fellatio* 1[29] 
Insertive fellatio* 0.5[29] 
* assuming no condom use 
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Since the beginning of the pandemic, three main transmission 
routes for HIV have been identified: 
Sexual route. The majority of HIV infections are acquired through 
unprotected sexual relations. Sexual transmission can occur when 
infected sexual secretions of one partner come into contact with the 
genital, oral, or rectal mucous membranes of another. 
• Blood or blood product route. This transmission route can 
account for infections in intravenous drug users, hemophiliacs 
and recipients of blood transfusions (though most transfusions 
are checked for HIV in the developed world) and blood 
products. Health care workers such as nurses, laboratory 
workers, and doctors, have also been infected, although this 
occurs more rarely. People who give and receive tattoos, 
piercings, and scarification procedures can also be at risk of 
infection. 
• Mother-to-child transmission (MTCT). The transmission of 
the virus from the mother to the child can occur in utero during 
the last weeks of pregnancy and at childbirth. In the absence of 
treatment, the transmission rate between the mother and child is 
25%.[26] However, where drug treatment and Cesarian section 
10 
                                                                       
are available, this can be reduced to 1%.[26] Breast feeding also 
presents a risk of infection for the baby. 
HIV-2 is transmitted much less frequently by the MTCT and 
sexual route than HIV-1. HIV has been found at low concentrations in 
the saliva, tears and urine of infected individuals, but there are no 
recorded cases of infection by these secretions and the potential risk of 
transmission is negligible.[32] The use of physical barriers such as the 
latex condom is widely advocated to reduce the sexual transmission of 
HIV. Spermicide, when used alone or with vaginal contraceptives like 
a diaphragm, actually increases the male to female transmission rate 
due to inflammation of the vagina; it should not be considered a 
barrier to infection.[33]  
Structure and genome 
 
It is about 120 nm in diameter (around 60 times smaller than a 
red blood cell) and roughly spherical.[34] 
 
 
11 
                                                                       
It is composed of two copies of positive single-stranded RNA 
that codes for the virus's nine genes enclosed by a conical capsid 
composed of 2,000 copies of the viral protein p24.[35]  
The single-stranded RNA is tightly bound to nucleocapsid 
proteins, p7 and enzymes needed for the development of the virion 
such as reverse transcriptase, proteases, ribonuclease and integrase. A 
matrix composed of the viral protein p17 surrounds the capsid 
ensuring the integrity of the virion particle.[36] This is, in turn, 
surrounded by the viral envelope which is composed of two layers of 
fatty molecules called phospholipids taken from the membrane of a 
human cell when a newly formed virus particle buds from the cell. 
Embedded in the viral envelope are proteins from the host cell and 
about 70 copies of a complex HIV protein that protrudes through the 
surface of the virus particle.[35] This protein, known as Env, consists of 
a cap made of three molecules called glycoprotein (gp) 120, and a 
stem consisting of three gp41 molecules that anchor the structure into 
the viral envelope.[36] This glycoprotein complex enables the virus to 
attach to and fuse with target cells to initiate the infectious cycle.[36] 
Both these surface proteins, especially gp120, have been considered as 
targets of future treatments or vaccines against HIV.[37] Of the nine 
genes that are encoded within the RNA genome, three of these genes, 
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gag, pol, and env, contain information needed to make the structural 
proteins for new virus particles.[35] env, for example, codes for a 
protein called gp160 that is broken down by a viral enzyme to form 
gp120 and gp41. The six remaining genes, tat, rev, nef, vif, vpr, and 
vpu (or vpx in the case of HIV-2), are regulatory genes for proteins 
that control the ability of HIV to infect cells, produce new copies of 
virus (replicate), or cause disease. [35] The protein encoded by nef, for 
instance, appears necessary for the virus to replicate efficiently, and 
the vpu-encoded protein influences the release of new virus particles 
from infected cells.[35] The ends of each strand of HIV RNA contain 
an RNA sequence called the long terminal repeat (LTR). Regions in 
the LTR act as switches to control production of new viruses and can 
be triggered by proteins from either HIV or the host cell. [35] 
Tropism 
The term viral tropism refers to which cell types HIV infects. 
HIV can infect a variety of immune cells such as CD4+ T cells, 
macrophages, and microglial cells. HIV-1 entry to macrophages and 
CD4+ T cells is mediated through interaction of the virion envelope 
glycoproteins (gp120) with the CD4 molecule on the target cells and 
also with chemokine coreceptors.[36] 
13 
                                                                       
Macrophage (M-tropic) strains of HIV-1, or non-syncitia-
inducing strains (NSI) use the β-chemokine receptor CCR5 for entry 
and are thus able to replicate in macrophages and CD4+ T cells.[38] 
Indeed, macrophages play a key role in several critical aspects of HIV 
infection. They appear to be the first cells infected by HIV and 
perhaps the source of HIV production when CD4+ cells become 
depleted in the patient. Macrophages and microglial cells are the cells 
infected by HIV in the central nervous system. In tonsils and adenoids 
of HIV-infected patients, macrophages fuse into multinucleated giant 
cells that produce huge amounts of virus 
T-tropic isolates, or syncitia-inducing (SI) strains replicate in 
primary CD4+ T cells as well as in macrophages and use the α-
chemokine receptor, CXCR4, for entry.[38][39][40] 
The α-chemokine, SDF-1, a ligand for CXCR4, suppresses 
replication of T-tropic HIV-1 isolates. It does this by down-regulating 
the expression of CXCR4 on the surface of these cells. HIV that use 
only the CCR5 receptor are termed R5, those that only use CXCR4 are 
termed X4, and those that use both, X4R5. However, the use of 
coreceptor alone does not explain viral tropism, as not all R5 viruses 
are able to use CCR5 on macrophages for a productive infection[38] 
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HIV can also infect a subtype of myeloid dendritic cells,[41] 
which probably constitute a reservoir that maintains infection when 
CD4+ T cell numbers have declined to extremely low levels. 
Sexual intercourse is the major mode of HIV transmission. Both 
X4 and R5 HIV are present in the seminal fluid which is passed from 
partner to partner.  
In patients infected with subtype B HIV-1, there is often a co-
receptor switch in late-stage disease and T-tropic variants appear that 
can infect a variety of T cells through CXCR4.[42] These variants then 
replicate more aggressively with heightened virulence that causes 
rapid T cell depletion, immune system collapse, and opportunistic 
infections that mark the advent of AIDS.[43] Thus, during the course of 
infection, viral adaptation to the use of CXCR4 instead of CCR5 may 
be a key step in the progression to AIDS. 
A number of studies with subtype B-infected individuals have 
determined that between 40 and 50% of AIDS patients can harbour 
viruses of the SI, and presumably the X4, phenotype.[44][45]  
 
 
15 
 
                                                                       
The HIV replication cycle 
Entry into the cell 
 
HIV enters macrophages and CD4+ T cells by the adsorption of 
glycoproteins on its surface to receptors on the target cell followed by 
fusion of the viral envelope with the cell membrane and the release of 
the HIV capsid into the cell.[46][47] 
Once HIV has bound to the target cell, the HIV RNA and 
various enzymes, including reverse transcriptase, integrase, 
ribonuclease and protease, are injected into the cell.[46] 
HIV can infect dendritic cells (DCs) by this CD4-CCR5 route, 
but another route using mannose-specific C-type lectin receptors such 
as DC-SIGN can also be used.[48] DCs are one of the first cells 
encountered by the virus during sexual transmission. They are 
currently thought to play an important role by transmitting HIV to T 
cells once the virus has been captured in the mucosa by DCs.[48] 
Replication and transcription 
Once the viral capsid enters the cell, an enzyme called reverse 
transcriptase liberates the single-stranded (+)RNA from the attached 
viral proteins and copies it into a complementary DNA.[49] This 
process of reverse transcription is extremely error-prone and it is 
16 
                                                                       
during this step that mutations may occur. Such mutations may cause 
drug resistance. The reverse transcriptase then makes a 
complementary DNA strand to form a double-stranded viral DNA 
intermediate (vDNA). This vDNA is then transported into the cell 
nucleus. The integration of the viral DNA into the host cell's genome 
is carried out by another viral enzyme called integrase. 
This integrated viral DNA may then lie dormant, in the latent 
stage of HIV infection. [49] To actively produce the virus, certain 
cellular transcription factors need to be present, the most important of 
which is NF-κB (NF kappa B), which is upregulated when T cells 
become activated.[50] This means that those cells most likely to be 
killed by HIV are in fact those currently fighting infection. 
In this replication process, the integrated provirus is copied to 
mRNA which is then spliced into smaller pieces. These small pieces 
produce the regulatory proteins Tat (which encourages new virus 
production) and Rev. As Rev accumulates it gradually starts to inhibit 
mRNA splicing.[51] At this stage, the structural proteins Gag and Env 
are produced from the full-length mRNA. The full-length RNA is 
actually the virus genome; it binds to the Gag protein and is packaged 
into new virus particles. 
17 
                                                                       
HIV-1 and HIV-2 appear to package their RNA differently; 
HIV-1 will bind to any appropriate RNA whereas HIV-2 will 
preferentially bind to the mRNA which was used to create the Gag 
protein itself. This may mean that HIV-1 is better able to mutate 
(HIV-1 infection progresses to AIDS faster than HIV-2 infection and 
is responsible for the majority of global infections). 
Assembly and release 
The final step of the viral cycle, assembly of new HIV-1 virons, 
begins at the plasma membrane of the host cell. The Env polyprotein 
(gp160) goes through the endoplasmic reticulum and is transported to 
the Golgi complex where it is cleaved by protease and processed into 
the two HIV envelope glycoproteins gp41 and gp120. These are 
transported to the plasma membrane of the host cell where gp41 
anchors the gp120 to the membrane of the infected cell. The Gag 
(p55) and Gag-Pol (p160) polyproteins also associate with the inner 
surface of the plasma membrane along with the HIV genomic RNA as 
the forming virion begins to bud from the host cell. Maturation either 
occurs in the forming bud or in the immature virion after it buds from 
the host cell. During maturation, HIV proteases cleave the 
polyproteins into individual functional HIV proteins and enzymes. 
The various structural components then assemble to produce a mature 
18 
                                                                       
HIV virion.[52] This cleavage step can be inhibited by protease 
inhibitors. The mature virus is then able to infect another cell. 
The clinical course of infection 
The initial infection with HIV generally occurs after transfer of 
body fluids from an infected person to an uninfected one.  
The first stage of infection, the primary, or acute infection, is a 
period of rapid viral replication that immediately follows the 
individual's exposure to HIV leading to an abundance of virus in the 
peripheral blood with levels of HIV commonly approaching several 
million viruses per mL.[53] This response is accompanied by a marked 
drop in the numbers of circulating CD4+ T cells. This acute viremia is 
associated in virtually all patients with the activation of CD8+ T cells, 
which kill HIV-infected cells, and subsequently with antibody 
production, or seroconversion. 
The CD8+ T cell response is thought to be important in 
controlling virus levels, which peak and then decline, as the CD4+ T 
cell counts rebound to around 800 cells per mL (the normal value is 
1200 cells per mL ). A good CD8+ T cell response has been linked to 
slower disease progression and a better prognosis, though it does not 
eliminate the virus.[54] 
19 
                                                                       
During this period (usually 2-4 weeks post-exposure) most 
individuals (80 to 90%) develop an influenza or mononucleosis-like 
illness called acute HIV infection, the most common symptoms of 
which may include fever, lymphadenopathy, pharyngitis, rash, 
myalgia, malaise, mouth and esophagal sores, and may also include, 
but less commonly, headache, nausea and vomiting, enlarged 
liver/spleen, weight loss, thrush, and neurological symptoms. Infected 
individuals may experience all, some, or none of these symptoms. 
Symptoms have an average duration of 28 days and usually last at 
least a week although duration of symptoms may vary.[55] Because of 
the nonspecific nature of these illnesses, it is often not recognized as a 
sign of HIV infection. Even if patients go to their doctors or a hospital, 
they will often be misdiagnosed as having one of the more common 
infectious diseases with the same symptoms. Consequently, these 
primary symptoms are not used to diagnose HIV infection as they do 
not develop in all cases and because many are caused by other more 
common diseases. However, recognizing the syndrome can be 
important because the patient is much more infectious during this 
period. 
20 
                                                                       
 
 
A generalized graph of the relationship between HIV copies (viral load) and CD4 
counts over the average course of untreated HIV infection; any particular 
individual's disease course may vary considerably.                      CD4+ T cell count (cells 
per µL)                      HIV RNA copies per mL of plasma 
A   strong    immune  defense   reduces    the    number    of       
viral     particles     in   the   blood   stream,   marking   the    start   of     
the  infection's   clinical    latency  stage. Clinical     latency   can         
vary between two weeks and 20 years. During this early phase of 
infection,     HIV    is   active   within  lymphoid   organs,    where       
large    amounts    of    virus     become     trapped    in    the    
follicular dendritic   cells   (FDC)    network.[56]   The    surrounding    
tissues       that    are   rich   in     CD4+ T cells   may   also   become  
infected,       and    viral    particles   accumulate   both   in     infected    
cells    and      as    free   virus.   Individuals   who   are   in   this   
phase    are              still    infectious.    During   this   time,   CD4+ 
CD45RO+ T cells         carry   most   of   the   proviral    load.[57] 
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When CD4+ T cell numbers decline below a critical level, cell-
mediated immunity is lost, and infections with a variety of 
opportunistic microbes appear. The first symptoms often include 
moderate and unexplained weight loss, recurring respiratory tract 
infections (such as sinusitis, bronchitis, otitis media, pharyngitis), 
prostatitis, skin rashes, and oral ulcerations. Common opportunistic 
infections and tumors, most of which are normally controlled by 
robust CD4+ T cell-mediated immunity then start to affect the patient.  
Typically, resistance is lost early on to oral Candida species and 
to Mycobacterium tuberculosis, which leads to an increased 
susceptibility to oral candidiasis (thrush) and tuberculosis. Later, 
reactivation of latent herpes viruses may cause worsening recurrences 
of herpes simplex eruptions, shingles, Epstein-Barr virus-induced B-
cell lymphomas, or Kaposi's sarcoma, a tumor of endothelial cells that 
occurs when HIV proteins such as Tat interact with Human 
Herpesvirus-8. Pneumonia caused by the fungus Pneumocystis 
jirovecii is common and often fatal. In the final stages of AIDS, 
infection with cytomegalovirus (another herpes virus) or 
Mycobacterium avium complex is more prominent. Not all patients 
with AIDS get all these infections or tumors, and there are other 
tumors and infections that are less prominent but still significant. 
22 
                                                                       
Over time the immune system becomes severely damaged by 
HIV. This is thought to happen for three main reasons:  
• The lymph nodes and tissues become damaged or 'burnt out' 
because of the years of activity; 
• HIV mutates and becomes more pathogenic, in other words 
stronger and more varied, leading to more T helper cell 
destruction; 
• The body fails to keep up with replacing the T helper cells that 
are lost. 
As the immune system fails, so symptoms develop. Initially 
many of the symptoms are mild, but as the immune system 
deteriorates the symptoms worsen.  
Sites of opportunistic infections and cancers : 
Symptomatic HIV infection is mainly caused by the emergence 
of opportunistic infections and cancers that the immune system would 
normally prevent. These can occur in almost all the body systems, but 
common examples are featured in the table below.  
As the table below indicates, symptomatic HIV infection is 
often characterised by multi-system disease. Treatment for the specific 
23 
                                                                       
infection or cancer is often carried out, but the underlying cause is the 
action of HIV as it erodes the immune system. Unless HIV itself can 
be slowed down the symptoms of immune suppression will continue 
to worsen.  
System Examples of Infection/Cancer 
Respiratory system 
• Tuberculosis (TB) 
• Pneumocystis carinii Pneumonia (PCP) 
• Kaposi's Sarcoma (KS) 
Gastro-intestinal system 
• Candida 
• Cryptosporidiosis 
• Cytomegalovirus (CMV) 
• Isosporiasis 
• Kaposi's Sarcoma 
• Giardiasis 
Central/peripheral Nervous system 
• HIV  encephalopathy 
• Cryptococcosis  
• Varicella Zoster 
• Herpes simplex 
• Cytomegalovirus 
• Toxoplasmosis 
• Non Hodgkin's lymphoma 
Skin 
• Herpes simplex 
• Varicella Zoster 
• Kaposi's sarcoma 
CDC Classification System for HIV Infection[58] [59]  
The CDC categorization of HIV/AIDS is based on the lowest 
documented CD4 cell count (Table 1) and on previously diagnosed 
HIV-related conditions (Tables 2 and 3). For example, if a patient had 
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a condition that once met the criteria for Category B but now is 
asymptomatic, the patient would remain in Category B. Additionally, 
categorization is based on specific conditions, as indicated below. 
Patients in categories A3, B3, and C1-C3 are considered to have 
AIDS.  
Table 1. CDC Classification System for HIV-Infected Adults and Adolescents 
Clinical Categories 
CD4 Cell 
Categories 
A 
Asymptomatic, Acute 
HIV, or PGL  
B 
Symptomatic Conditions,#* 
not A or C  
C 
AIDS-Indicator 
Conditions* 
(1) ≥500 
cells/µL 
A1 B1 
C1 
(2) 200-499 
cells/µL 
A2 B2 
C2 
(3) <200 
cells/µL 
A3 B3 C3 
 
Key to abbreviations: CDC = U.S. Centers for Disease Control and Prevention; PGL = persistent 
generalized lymphadenopathy.  
# For symptomatic conditions, see Table 2. * For AIDS-indicator conditions, see Table 3. 
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Table 2. CDC Classification System: Category B Symptomatic Conditions  
Category B symptomatic conditions are defined as symptomatic conditions 
occurring in an HIV-infected adolescent or adult that meet at least 1 of the 
following criteria: 
a) They are attributed to HIV infection or indicate a defect in cell-mediated 
immunity.  
b) They are considered to have a clinical course or management that is 
complicated by HIV infection.  
Examples include, but are not limited to, the following: 
 Bacillary angiomatosis  
 Oropharyngeal candidiasis (thrush)  
 Vulvovaginal candidiasis, persistent or resistant  
 Pelvic inflammatory disease (PID)  
 Cervical dysplasia (moderate or severe)/cervical carcinoma in situ  
 Hairy leukoplakia, oral  
 Idiopathic thrombocytopenic purpura  
 Constitutional symptoms, such as fever (>38.5°C) or diarrhea lasting >1 
month  
 Peripheral neuropathy  
 Herpes zoster (shingles), involving ≥2 episodes or ≥1 dermatome 
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Table 3. CDC Classification System: Category C AIDS-Indicator Conditions 
 Bacterial pneumonia, recurrent (≥2 episodes in 12 months)  
 Candidiasis of the bronchi, trachea, or lungs  
 Candidiasis, esophageal  
 Cervical carcinoma, invasive, confirmed by biopsy  
 Coccidioidomycosis, disseminated or extrapulmonary  
 Cryptococcosis, extrapulmonary  
 Cryptosporidiosis, chronic intestinal (>1-month duration)  
 Cytomegalovirus disease (other than liver, spleen, or nodes)  
 Encephalopathy, HIV-related  
 Herpes simplex: chronic ulcers (>1-month duration), or bronchitis, 
pneumonitis, or esophagitis  
 Histoplasmosis, disseminated or extrapulmonary  
 Isosporiasis, chronic intestinal (>1-month duration)  
 Kaposi sarcoma  
 Lymphoma, Burkitt, immunoblastic, or primary central nervous system  
 Mycobacterium avium complex (MAC) or M kansasii, disseminated or 
extrapulmonary  
 Mycobacterium tuberculosis, pulmonary or extrapulmonary  
 Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary  
 Pneumocystis jiroveci (formerly carinii) pneumonia (PCP)  
 Progressive multifocal leukoencephalopathy (PML)  
 Salmonella septicemia, recurrent (nontyphoid)  
 Toxoplasmosis of brain  
 Wasting syndrome due to HIV (involuntary weight loss >10% of 
baseline body weight) associated with either chronic diarrhea (≥2 loose 
stools per day ≥1 month) or chronic weakness and documented fever ≥1 
month 
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WHO clinical staging of HIV disease in adults and adolescents 
(2006 revision) [58] [59]  
 Staging is based on clinical findings that guide the diagnosis, 
evaluation, and management of HIV/AIDS, and does not require a 
CD4 cell count. This staging system is used in many countries to 
determine eligibility for antiretroviral therapy. Clinical stages are 
categorized as 1 through 4, progressing from primary HIV infection to 
advanced HIV/AIDS. These stages are defined by specific clinical 
conditions or symptoms. For the purpose of the WHO staging system, 
adolescents and adults are defined as individuals aged ≥15 years. 
WHO Clinical Staging of HIV/AIDS for Adults and Adolescents 
(Interim Definitions) 
Primary HIV Infection 
 Asymptomatic  
 Acute retroviral syndrome 
Clinical Stage 1 
 Asymptomatic  
 Persistent generalized lymphadenopathy 
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Clinical Stage 2 
 Moderate unexplained weight loss (<10% of presumed or 
measured body weight)  
 Recurrent respiratory infections (respiratory tract infections, 
upper respiratory infections, sinusitis, bronchitis, otitis media, 
pharyngitis)  
 Herpes zoster  
 Minor mucocutaneous manifestations (angular cheilitis, 
recurrent oral ulcerations, seborrheic dermatitis, prurigo, papular 
pruritic eruptions, fungal fingernail infections) 
Clinical Stage 3 
Conditions for which a presumptive diagnosis can be made on the 
basis of clinical signs or simple investigations 
Severe weight loss (>10% of presumed or measured body weight)  
Unexplained chronic diarrhea for >1 month  
Unexplained persistent fever for >1 month (intermittent or 
constant)  
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Oral candidiasis (thrush)  
Oral hairy leukoplakia  
Pulmonary tuberculosis within the last 2 years  
Severe presumed bacterial infections (eg, pneumonia, empyema, 
pyomyositis, bone or joint infection, meningitis, bacteremia)  
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Conditions for which confirmatory diagnostic testing is necessary 
Unexplained anemia (hemoglobin <8 g/dL)  
Neutropenia (neutrophils <500 cells/µL)  
 Thrombocytopenia (platelets <50,000 cells/µL) 
Clinical Stage 4 
Conditions for which a presumptive diagnosis can be made on the 
basis of clinical signs or simple investigations 
HIV wasting syndrome, as defined by the CDC (see Table 3, 
above)  
Pneumocystis jiroveci (formerly carinii) pneumonia  
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Recurrent severe or radiologic bacterial pneumonia  
Chronic herpes simplex infection (oral or genital, or anorectal site) 
for >1 month  
Esophageal candidiasis  
Extrapulmonary tuberculosis  
Kaposi sarcoma  
Central nervous system toxoplasmosis  
HIV encephalopathy 
Conditions for which a confirmatory diagnostic testing is 
necessary 
Cryptococcosis, extrapulmonary  
Disseminated nontuberculosis Mycobacteria infection  
Progressive multifocal leukoencephalopathy  
Candida of the trachea, bronchi, or lungs  
Cryptosporidiosis  
Isosporiasis  
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Visceral herpes simplex infection, cytomegalovirus infection 
(retinitis or organ other than liver, spleen, or lymph node)  
Any disseminated mycosis (eg, histoplasmosis, 
coccidioidomycosis, penicilliosis)  
Recurrent nontyphoidal Salmonella septicemia  
Lymphoma (cerebral or B-cell non-Hodgkin)  
Invasive cervical carcinoma  
Visceral leishmaniasis 
 HIV encephalopathy: clinical findings of disabling cognitive 
and/or motor dysfunction interfering with activities of daily living, 
progressing over weeks to months, in the absence of a concurrent 
illness or condition other than HIV infection which could explain the 
findings. 
HIV test 
HIV-1 testing consists of initial screening with an enzyme-
linked immunosorbent assay (ELISA) to detect antibodies to HIV-1. 
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Confirmatory testing with a more specific supplemental test 
(e.g., Western blot or, less commonly, an immunofluorescence assay 
(IFA)) 
Generally, a second specimen should be collected more than a 
month later and retested for persons with indeterminate Western blot 
results 
Nucleic acid testing (e.g., viral RNA or proviral DNA 
amplification method) can also help diagnosis in certain situations.[60] 
In addition, a few tested specimens might provide inconclusive 
results because of a low quantity specimen. In these situations, a 
second specimen is collected and tested for HIV infection. 
Treatment 
There is currently no vaccine or cure for HIV or AIDS. The 
only known method of prevention is avoiding exposure to the virus. 
However, an antiretroviral treatment, known as post-exposure 
prophylaxis is believed to reduce the risk of infection if begun directly 
after exposure.[61] Current treatment for HIV infection consists of 
highly active antiretroviral therapy, or HAART.[62] 
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Classes of antiretroviral drugs 
Antiretroviral drugs are broadly classified by the phase of the 
retrovirus life-cycle that the drug inhibits. There are thus six broad 
classifications of antiretroviral drugs in development, though only the 
first three classes currently have licensed examples: 
• Reverse transcriptase inhibitors (RTIs) target construction of 
viral DNA by inhibiting activity of reverse transcriptase. There 
are two subtypes of RTIs with different mechanisms of action: 
nucleoside-analogue RTIs are incorporated into the viral DNA 
leading to chain termination, while non-nucleoside-analogue 
RTIs distort the binding potential of the reverse transcriptase 
enzyme.  
• Protease inhibitors (PIs) target viral assembly by inhibiting the 
activity of protease, an enzyme used by HIV to cleave nascent 
proteins for final assembly of new virons.  
• Fusion inhibitors block HIV from fusing with a cell's membrane 
to enter and infect it. There is currently only one FDA-approved 
drug in this class, enfuvirtide,  
• Integrase inhibitors inhibit the enzyme integrase, which is 
responsible for integration of viral DNA into the DNA of the 
infected cell. There are several integrase inhibitors currently 
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under clinical trial, and raltegravir became the first to receive 
FDA approval in October 2007.  
• Entry inhibitors block HIV-1 from the host cell by binding 
CCR5, a molecule on the host membrane termed a co-receptor 
that HIV-1 normally uses for entry into the cell together with a 
primary receptor. Only one entry-inhibitor class drug is 
available, maraviroc.  
• Maturation inhibitors inhibit the last step in gag processing in 
which the viral capsid polyprotein is cleaved, thereby blocking 
the conversion of the polyprotein into the mature capsid protein 
(p24). Because these viral particles have a defective core, the 
virions released consist mainly of non-infectious particles. 
Bevirimat is the only drug that is currently under 
investigation.[63]  
• Portmanteau inhibitors A new way to combat HIV through the 
merging of two antiviral agents into one drug, achieving the 
same effect as when two or more drugs are taken separately.  
Combination therapy 
• antiretroviral combination therapy defends against resistance by 
suppressing HIV replication as much as possible. 
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• Combinations of antiretrovirals create multiple obstacles to HIV 
replication to keep the number of offspring low and reduce the 
possibility of a superior mutation. If a mutation arises that 
conveys resistance to one of the drugs being taken, the other 
drugs continue to suppress reproduction of that mutation. 
• Combinations usually comprise two nucleoside-analogue RTIs 
and one non-nucleoside-analogue RTI or protease inhibitor.[64] 
This three drug combination is commonly known as a triple 
cocktail.[65] 
• Combinations of antiretrovirals are subject to positive and 
negative synergies, which limits the number of useful 
combinations. 
• Other issues further limit some people's treatment options from 
antiretroviral drug combinations, including their complicated 
dosing schedules and often severe side effects. 
Current treatment guidelines 
The current guidelines for antiretroviral therapy (ART) from the 
World Health Organization reflect the 2003 changes to the guidelines 
and recommend that in resource-limited settings (that is, developing 
nations), HIV-infected adults and adolescents should start ART when 
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HIV infection has been confirmed and one of the following conditions 
is present [66]): 
• Clinically advanced HIV disease;  
• WHO Stage IV HIV disease, irrespective of the CD4 cell count;  
• WHO Stage III disease with consideration of using CD4 cell 
counts less than 350/µl to assist decision making;  
• WHO Stage I or II HIV disease with CD4 cell counts less than 
200/µl.  
The current guidelines for adults and adolescents were stated on 
October 6, 2005 [67]: 
• All patients with history of an AIDS-defining illness or severe 
symptoms of HIV infection regardless of CD4+ T cell count 
receive ART.  
• Antiretroviral therapy is also recommended for asymptomatic 
patients with less than 200 CD4+ T cells/µl.  
• Asymptomatic patients with CD4+ T cell counts of 201–350 
cells/µl should be offered treatment.  
• For asymptomatic patients with CD4+ T cell of greater than 350 
cells/µl and plasma HIV RNA greater than 100,000 copies/ml, 
37 
                                                                       
most experienced clinicians defer therapy but some clinicians 
may consider initiating treatment.  
• Therapy should be deferred for patients with CD4+ T cell 
counts of greater than 350 cells/µl and plasma HIV RNA less 
than 100,000 copies/mL.  
 
The preferred initial regimens are[68]: 
• efavirenz + zidovudine + lamivudine  
• efavirenz + tenofovir + emtricitabine  
• lopinavir boosted with ritonavir + zidovudine + lamivudine  
• lopinavir boosted with ritonavir + tenofovir + emtricitabine.  
Postexposure Prophylaxis [PEP] 
                         In 2005, the Centers for Disease Control and 
Prevention in the United States recommended a 28-day HIV drug 
regimen for those who have been exposed to HIV (HIV 
Postexposure Prophylaxis [PEP])[69]. The drugs have demonstrated 
effectiveness in preventing the virus nearly 100% of the time in 
those who received treatment within the initial 24 hours of 
exposure. The effectiveness falls to 52% of the time in those who 
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are treated within 72 hours; those not treated within the first 72 
hours are not recommended candidates for the regimen. 
Adverse effects 
Adverse effects of antiretroviral drugs vary by drug, by 
ethnicity, and by individual, and by interaction with other drugs, 
including alcohol. Hypersensitivity to some drugs may also occur in 
some individuals. The following list is not complete, but includes 
several of the common adverse effects experienced by patients taking 
some antiretroviral drugs:  
• Abdominal pain , Alopecia, Anemia, Asthenia  
• Change in taste perception  
• Diarrhea, Dizziness (Vertigo)  
• Fanconi syndrome , Flatulence  
• Headache, Hepatitis, Hyperbilirubinemia, Hypercholesterolemia 
(Dyslipidemia, Hyperlipidemia, high cholesterol)  
• Hyperpigmentation (of nails, palms, or soles)  
• Ingrown nails, Insomnia  
• Jaundice  
• Lipodystrophy, Liver failure  
• Malaise, confusion, Myalgia  
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• Myalgic Encephalomyelitis (chronic fatigue syndrome),  
• Myopathy  
• Nausea, Neutropenia, Nightmares  
• Oral ulcers  
• Pancreatitis , Paresthesia (numbness), Peripheral neuropathy  
• Rash, Renal failure or insufficiency  
• Somnolence (drowsiness), Stevens-Johnson syndrome  
• Vomiting  
• Xeroderma (dry skin)  
HAART allows the stabilisation of the patient’s symptoms and 
viremia, but it neither cures the patient, nor alleviates the symptoms, 
and high levels of HIV-1, often HAART resistant, return once 
treatment is stopped. Moreover, it would take more than a lifetime for 
HIV infection to be cleared using HAART. Despite this, many HIV-
infected individuals have experienced remarkable improvements in 
their general health and quality of life, which has led to a large 
reduction in HIV-associated morbidity and mortality in the developed 
world. A computer based study in 2006 projected that following the 
2004 United States treatment guidelines gave an average life 
expectancy of an HIV infected individual to be 32.1 years from the 
time of infection if treatment was started when the CD4 count was 
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350/µL. This study was limited as it did not take into account possible 
future treatments and the projection has not been confirmed within a 
clinical cohort setting. In the absence of HAART, progression from 
HIV infection to AIDS has been observed to occur at a median of 
between nine to ten years and the median survival time after 
developing AIDS is only 9.2 months. However, HAART sometimes 
achieves far less than optimal results, in some circumstances being 
effective in less than fifty percent of patients. This is due to a variety 
of reasons such as medication intolerance/side effects, prior 
ineffective antiretroviral therapy and infection with a drug-resistant 
strain of HIV. However, non-adherence and non-persistence with 
antiretroviral therapy is the major reason most individuals fail to 
benefit from HAART. The reasons for non-adherence and non-
persistence with HAART are varied and overlapping. Major 
psychosocial issues, such as poor access to medical care, inadequate 
social supports, psychiatric disease and drug abuse contribute to non-
adherence. The complexity of these HAART regimens, whether due to 
pill number, dosing frequency, meal restrictions or other issues along 
with side effects that create intentional non-adherence also contribute 
to this problem. The side effects include lipodystrophy, dyslipidaemia, 
insulin resistance, an increase in cardiovascular risks and birth defects. 
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MATERIAL AND METHODS 
The present study was conducted at Coimbatore medical college 
hospital, Coimbatore. Descriptive study of HIV positive in-patient of 
Department of Medicine, Coimbatore medical college hospital, 
Coimbatore. All patients were HIV test positive as determined by 
ELISA method, using two different antigens and a rapid test as 
recommended by National AIDS Control Organization (NACO). A 
total of 100 HIV seropositive patients admitted in Coimbatore medical 
college hospital, Coimbatore, during January 2006 to June 2007 were 
investigated for various opportunistic pathogens. Patients on Highly 
Active Anti-Retro Viral Therapy were not included in the study. A 
written informed consent was taken from all the patients. The 
information on each patient’s occupation, education, medical history 
and physical examination was recorded. Laboratory results and 
clinical findings were used for making the definitive or presumptive 
diagnosis of each infection. 
Basic investigations like urine complete examination, complete 
haemogram, blood sugar, urea, serum creatinine, electrolytes, liver 
function tests, ECG, X-ray chest, ultrasonogram abdomen were done. 
Pleural fluid analysis, cerebrospinal fluids (CSF) analysis, computed 
tomography were done in relevant cases.  
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Various samples e.g.: sputum, blood, stool, urine, cerebrospinal fluids 
(CSF), lymph node aspirate were collected as per symptoms and 
clinical presentations under universal aseptic precautions in suitable 
sterile containers. Specimens were stained using appropriate stains e.g. 
Gram, Giemsa, Ziehl - Neelson and examined under microscope. CSF 
samples were examined for Cryptococcus by Indian ink wet mount. 
Appropriate media like Blood agar, MacConkey agar, Chocolate agar 
and Sabourauds Dextrose agar were used for isolation of pathogens. 
The pathogens isolated were further identified following standard 
protocol. 
 The sera were examined for Syphilis (VDRL test), Hepatitis B 
(HbsAg), Typhoid (Widal test). Statistical analysis was done using 
proportions. 
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OBSERVATION  AND RESULTS 
 
                                                                       
 
OBSERVATIONS 
TABLE – 1 
AGE AND SEX DISTRIBUTION  
Male [n=80] Female [n=20] TOTAL [n=100] Age 
No. % No. % No. % 
10 – 19 1 1.25% 1 5% 2 2% 
20 – 29 8 10% 4 20% 12 12% 
30 – 39 43 53.75% 9 45% 52 52% 
40 – 49 22 27.5% 4 20% 26 26% 
50 – 60 6 7.5% 2      10%       8 8% 
15-44 65 81.25% 17      85%      82 82% 
 
A total of 100 HIV seropositive patients were included in the study group. The age 
and sex distribution of the cases is shown in the [Table - 1]. 20% were females 
and 80% were males. The most common age group infected had age in the range 
of 30-39 years, followed by 40-49 years and 20-29 years. 
AGE AND SEX DISTRIBUTION 
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TABLE – 2 
MARITAL STATUS - SEX WISE ANALYSIS 
 
Male [n=80] Female [n=20] TOTAL [ n=100]  
Marital Status No. % No. % No. % 
Married 59 73.75% 13 65% 73 73% 
Unmarried 16 20% _ _ 16 16% 
Separated 6 7.5% 2 10% 7 7% 
Widow _ _ 5 25% 5 5% 
 
Marital Status of the cases is shown in the [Table - 2]. Majority of the 
male patients were married (73.75%), 20% were not married and 7.5% 
were separated. All female patients in the study group were married 
and 25% were widow.  
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TABLE – 3 
OCCUPATON - SEX WISE ANALYSIS 
 
Male [n=80] Female [n=20] TOTAL [ n=100]  
Occupation No. % No. % No %. 
Labourer  32 40% 4 20% 36 36% 
Driver 17 21.25% - - 17 17% 
Business 11 13.75% - - 12 12% 
Agriculture 5 6.25% 2 10% 7 7% 
At Home 2 2.5% 13 65% 15 15% 
Others 13 16.25% 1 5% 13 13% 
                               Others - Painter, Cook, Electrician, Handcraft, Iron casting, Videographer, Gold smith.           
     
                                                          
 Occupation of the cases is shown in the [Table - 3].  It was seen that 
21.5% of the affected males were drivers and 40% were labourers. 
Most of the [65%]  affected females were housewives and 20% were 
labourers.  
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                                                            TABLE – 4 
LITERACY STATUS - SEX WISE ANALYSIS 
 
Male [n=80] Female [n=20] TOTAL[ n=100]  
Education No. % No. % No. % 
Illiterate 29 36.25% 10 50% 39 39% 
Primary Education 15 18.75% 7 35% 22 22% 
Secondary Education up to 8th std 20 25% 2 10% 22 22% 
Higher secondary 16 20% 1 5% 17 17% 
 
Literacy status of the cases is shown in the [Table - 4]. Most of the 
[39%] affected patients were illiterate. 
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TABLE – 5 
 
DURATION OF POSITIVITY KNOWN TO THE PATIENT 
Duration of positivity known No of cases % 
 < 1 Month  30 30% 
 1to 6 Months   52 52% 
 6 Months to 1 year 6 6% 
 >1 year  12 12% 
 
Table -5 shows the duration of positivity known to the patient. 30% of 
cases came to know about their HIV positivity status only after 
admission in hospital for their illness. 52% were aware for about 1to 6 
months.  
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TABLE – 6 
MODE OF TRANSMISSION OF HIV 
 
Male [n=80] Female [n=20] TOTAL[ n=100] Mode of 
Transmission No. % No. % No. % 
Pre marital contact 41 51.25% _ _ 41 41% 
Extra marital  46 57.5% 2 10% 48 48% 
Marital  - - 18 90% 18 18% 
Vertical transmission 1 1.25% _ _ 1 1% 
 
Mode of transmission of HIV is shown in the [Table - 6]. Most 
common mode of transmission of HIV infection is sexual. Most of the 
male patients were married and had history of extramarital contact 
[57.5%], 51.25% had history of premarital contact and one case 
acquired through vertical transmission. Among females 90% acquired 
infection through their husbands and 10% through extra marital 
contact. 
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TABLE – 7 
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ASSOCIATED CLINICAL SYMPTOMS IN HIV POSITIVE PATIENTS  
 
< 1 Month > 1 Month TOTAL 
SYMPTOMS No of cases 
No. % No. % No. % 
Fever 81 25 30.86% 56 69.13% 81 81% 
Cough with expectoration 46 19 41.3% 27 58.69% 46 46% 
Appetite loss, weight loss 85 4 5.8 81 95.2% 85 85% 
Tiredness 84 7 8.4 77 91.6% 84 84% 
Head ache 36 25 69.44 11 30.56% 36 36% 
Oral ulcer 35 13 37.2% 22 62.8% 35 35% 
Painful swallowing 26 18 69.2% 8 30.8% 26 26% 
Skin lesion 26 4 15.4 22 84.6% 26 26% 
Loose stools 16 5 31.25% 11 68.75% 16 16% 
Genital ulcer 15 6 40% 9 60% 15 15% 
 
Associated clinical symptoms in HIV positive patients are shown in the [Table - 7].  
Appetite loss, weight loss [85%] and tiredness [84%] were the commonest 
presenting symptoms followed by fever[81%], cough with expectoration[46%], 
head ache[36%], oral ulcer[35%], painful swallowing[26%], skin lesion[26%], 
loose stools[16%] and genital ulcer[15%]. 
            
ASSOCIATED CLINICAL SYMPTOMS IN HIV 
POSITIVE PATIENTS 
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                                                    TABLE – 8 
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ASSOCIATED CLINICAL SIGNS IN HIV POSITIVE PATIENTS 
Signs No of cases % 
Wasting  91 91% 
Fever 82 82% 
Pallor  81 81% 
Oral candidiasis  67 67% 
Glossitis 52  52% 
Black Nails  36 36% 
Lymphadenopathy 32 32% 
Oral hairy leukoplakia 17 17% 
Genital lesion 16 16% 
Seborrhoeic Dermatitis  4 4% 
Herpes zoster 1 1% 
Chronic Pruritic papular dermatitis 14 14% 
Dyspnoea 27 27% 
Pedal edema 21 21% 
Retinopathy 3 3% 
 
Associated clinical signs in HIV positive patients are shown in the 
[Table - 8]. Examination revealed that the patients had multi system 
involvement. 91% of patients had developed AIDS related cachexia 
also known as ‘wasting syndrome’. 82% of cases  had fever , 70% 
were anaemic, 67% had oral candidiasis, 52% had Glossitis, nails of 
36% of the cases showed black discolouration[black nails], 36% had 
lymphadenopathy, 17% had oral hairy leukoplakia, 16% had genital 
lesion, 14% had chronic pruritic papular dermatitis, 4% had 
Seborrhoeic dermatitis, 3% had retinopathy and 1% had herpes zoster. 
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  Herpes zoster                                                     oral candidiasis    
 
                                                        
                                                                                                                                                                     
                  
   Oral hairy leukoplakia                                 Seborrhoeic Dermatitis                  
                                                                             
                                                                                                                      
                                                         
 
                                                      Cold abscess                          
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                                                              TABLE – 9 
LYMPHADENOPATHY 
Lymphadenopathy No of cases % 
Cervical  21 21% 
Cervical, Axillary  8 8% 
Generalized 3 3% 
Abdominal Lymphadenopathy 16 16% 
Table 9 show that cervical lymphadenopathy was present in 21% of 
cases, 8% presented with cervical and axillary node enlargement, 3% 
had generalized lymphadenopathy and 16% had abdominal 
lymphadenopathy [ultra sonogram abdomen]. 
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                                                      TABLE –10 
GENITAL LESION 
Male n=80 Female n=20  Total n=100 Genital Lesion 
No. % No. % No. % 
Genital Herpes 8 10% 6 30% 14 14% 
Wart  _ _ 1 5% 1 1% 
Cervical  Carcinoma _ _ 1 5% 1 1% 
 
Table 10 shows that 10% of male cases and 30% of female cases had 
genital herpes.  Of the female cases 5% had genital wart and another 
5% had cervical carcinoma. 
TABLE – 11 
CLINICAL FINDINGS ON EXAMINATION OF THE ABDOMEN 
 No. of cases % 
Doughy Abdomen 7 7% 
Hepatomegaly  33 33% 
Splenomegaly 10 10% 
Hepatosplenomegaly 2 2% 
Ascites  5 5% 
 
Clinical finding on examination of the abdomen is shown in the Table 
11. 7% had doughy abdomen 33% of the cases had hepatomegaly, 
10% had splenomegaly, and 2% had hepatosplenomegaly. 
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INVESTIGATIONS 
TABLE – 12 
Urine Culture 
Organism growth 
No of cases % 
Escherichia coli 4 4% 
Proteus  2 2% 
Klebsiella pneumonia 1 1% 
Urine culture report is shown in Table 12. 
4% showed growth of Escherichia coli, 2% Proteus and 1% Klebsiella 
pneumonia. 
 
TABLE – 13 
Anaemia                                                                                             
Table 13 shows 70% of cases were moderately anaemic and 24% were 
severely anaemic.   
 
 
TABLE 14 
SPUTUM AFB POSITIVE 
Table 14 shows sputum smear for AFB was positive in 16% of the 
cases. 
                                                
 
 
 
Hemoglobin gm % No of cases % 
<7 24 24% 
7.1 – 10.9 70 70% 
> 11 6 6% 
No of cases 16 
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                                                          TABLE 15 
SPUTUM CULTURE 
 No of cases % 
Proteus  2 2 
Klebsiella Pneumonia 6 6 
Aspergillus niger 1 1 
Aceneto bacter 1 1 
E.coli 2 2 
 
Table 15 shows sputum culture report. 6% of the cases showed the 
growth of Klebsiella pneumonia, 2% showed E.coli, 2% showed 
Proteus, 1% Aspergillus niger and 1% Aceneto bacter. 
 
TABLE – 16 
X – RAY CHEST  
 No of cases % 
Pleural effusion  14 14% 
Consolidation 10 10% 
Upper lobe fibrosis 2 2 
 
X-ray features of the cases are shown in the Table 16. 
14% showed pleural effusion, 10% showed consolidation and 2% 
showed upper lobe fibrosis. 
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TABLE – 17 
USG - ABDOMEN 
 No of cases % 
Abdominal 
lymphadenopathy  
16 16 
Hepatosplenomegaly 9 9 
Hepatomegaly 34 34 
Splenomegaly  10 10 
Ascites 5 5 
  
Findings of ultra sonogram abdomen of the cases are shown in the 
Table 17. Abdominal lymphadenopathy was found in 16% of the 
cases, hepatomegaly in 34%, splenomegaly in 10%, 
hepatosplenomegaly in 9% and ascites in 5%.                                                                   
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Associated clinical conditions in HIV positive patients  are shown in 
Tables 18, 19, 20 and 21. 
TABLE – 18 
ASSOCIATED CLINICAL CONDITIONS IN HIV POSITIVE PATIENTS  
  
n=42 N=100 Respiratory system 
No.  % No. % 
Sputum AFB Positive 
Pulmonary tuberculosis  
16 38.0% 16 16% 
Klebsiella pneumonia  6 14.28% 6 6% 
Tuberculous  Pleural 
effusion  
14 33.33% 14 14% 
Other bacterial infections  6 14.28% 6 6% 
TOTAL 42 100% 42 42% 
 
Respiratory system disorder is shown in the Table 18.  
Among the 100 cases 42% had respiratory illness. 
38% of the respiratory illness was sputum smear positive tuberculosis, 
33% was tuberculous pleural effusion and 28.5% were other bacterial 
infections. 
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TABLE – 19 
GASTROINTESTINAL SYSTEM 
 No of cases % 
Oral Candidiasis 67 67% 
Esophageal Candidiasis 26 26% 
Oral hairy leukoplakia 17 17% 
Abdominal Tuberculosis  8 8% 
Gastroenteritis 17 17% 
Hepatitis – B. Infection  1 1% 
 
Table 19 shows the gastrointestinal manifestations in the study group. 
67% had oral Candidiasis, 26% had esophageal candidiasis, 17% had 
gastroenteritis, 17% had oral hairy leukoplakia, 8% had abdominal 
tuberculosis and 1% had acute Hepatitis B virus infection.  
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                                                           TABLE – 20 
CENTRAL NERVOUS SYSTEM 
n=33 n=100  No of 
cases 
% No.  % 
Cryptococcal Meningitis   15 45.45% 15 15% 
Tuberculous Meningitis  6 18.18% 6 6% 
Candidial Meningitis  2 6% 2 2% 
HIV encephalitis 2  6% 2 2% 
Tuberculoma  2 6% 2 2% 
Toxoplasmosis 1 3% 1 1% 
CMV retinitis 1 3% 1 1% 
HIV retinopathy  2 6% 2 2% 
Neurocysticercosis  1 3% 1 1% 
Brain Abscess  1 3% 1 1% 
TOTAL 33 100% 33 33% 
 
Table 20 shows the Central Nervous System manifestations in the 
study group. 
Of the 100 cases 33 presented with Central Nervous System 
manifestations. Among them 45.45% was Cryptococcal meningitis, 
18.18% was tuberculous meningitis, 6% was Candidial meningitis, 6% 
was HIV encephalitis, 6% was Tuberculoma and 6% was found to 
have HIV retinopathy.Others including CMV retinitis, Toxoplasmosis, 
Neurocysticercosis and Brain Abscess -3% each were also found.  
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TABLE – 21 
TUBERCULOSIS  
         
n=47 
  
n=100 
  
No. of 
cases     %    % 
Pulmonary   16 34.04% 16% 
Extra pulmonary  31 65.95% 31% 
TOTAL 47 47% 47% 
Pulmonary  and  Extra 
pulmonary tuberculosis 
4 8.51% 4% 
Tuberculous abdomen and 
cervical lymphadenitis 
4 8.51% 4% 
Extra pulmonary tuberculosis 
Pleural effusion 14 29.78% 14% 
Tuberculous Abdomen 9 17.02% 9% 
Tuberculous Meningitis  6 12.76% 6% 
Cold Abscess 4 8.51% 4% 
Tuberculoma 2 4.25% 2% 
 
Various presentation of tuberculosis is shown in Table 21. 
Of the 100 cases 47 cases presented with tuberculosis. Among them 
65.9% had extra pulmonary and 34% had pulmonary tuberculosis. 
8.5% had both pulmonary  and  extra pulmonary tuberculosis and 
another 8.5% had tuberculosis of  abdomen and cervical 
lymphadenitis. Among extra pulmonary tuberculosis 29.7% was 
Pleural effusion, 17% was Tuberculous Abdomen, 12.76% was 
Tuberculous Meningitis, 8.5%  was cold  Abscess and 4.25% was 
Tuberculoma. 
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DISCUSSION  
Although the Human Immunodeficiency Viruses are the initial 
causative agents in AIDS, most of the morbidity and mortality seen in 
the case of AIDS patient results from the opportunistic infections 
which take advantage of the lowered cellular and humoral defences of 
the patient. A wide variety of these infections are encountered in the 
AIDS population, including bacteria, fungi, viruses and protozoa. 
Very often, these represent not new infections but the reactivation of 
old infection.[72] 
In the present study out of 100 HIV positive patients 80% were males 
and 20% were females. This is similar to NACO findings [70]: Strong 
association between HIV positivity and sex is found that males are 
more affected. 
                     The age ranged between 13 to 60 in males and 19 to 53 in 
females. The maximum number of patients was in the 30-39 years age 
group followed by 40-49 years. 81.25% of males and 85% of females 
were in sexually active and economically productive group of 15 to 44 
years. This population yet not done adequately for their family and is 
going to leave orphans and widows who are HIV positive.  
                      Poor literacy status is associated with high rate of 
infection [71]  
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probably because of low awareness levels about risk factors among 
them the low self estimate may provoke them taking more risk.  
                     The commonest mode of transmission (99%) was due to 
sexual contact. Most of the males were married and 57% had history 
of extra marital sexual contact and 51% had premarital contact. 20% 
of the males were unmarried. One case had acquired HIV infection 
from his infected parents who died of AIDS. 
                     In males the commonest occupation was driver [21.25%], 
followed by laborer in various fields [40%].  
                     The HIV infection in females revealed a sorry story in 
our population. Most of the females were homemakers and 20% were 
labourers. Two persons gave history of extra marital sexual contact. 
Women are at the mercy of their counterparts and are silent sufferers, 
they do not have the right to ask for contraception and suffer a deadly 
disease just because of their partners. 
                     50% of the cases came to know about their HIV 
positivity status only after hospitalization. 
                    All the patients presented with more than one symptom.  
Appetite loss [85%] and tiredness [84%] were the commonest 
presenting symptoms followed by weight loss of more than 10% 
(85%). Fever of more than 1 month duration was found in nearly 
69.13% of these patients, while cough (46%), head ache [36%], skin 
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lesions [26%] and diarrhoea (16%) were the other common 
manifestations seen among the patients studied. (32%) patients 
presented with lymphadenopathy. Cervical lymph nodes were the 
commonest lymph nodes found to be enlarged and were seen in 21% 
of the patients.  These observations are similar to those in the study 
published in 124 Journal, Indian Academy of Clinical Medicine _ Vol. 
4, No. 2 _ April-June 2003.  
                  81% of the cases were anaemic. 
                 Oral candidiasis was the most common (67%) opportunistic 
infection and our finding is similar to the report of NACO[73] and T 
K Giri et al. [73] But Kaur et a1[74] from Vellore have reported oral 
candidiasis as the second most common infection in AIDS patients. 
Ayyagari et a1[75] have reported very low incidence of candidiasis 
(27.7%). 
 26 patients had symptom of dysphagia and were found to be having 
oral and esophageal candidiasis. Presence of oral candidiasis and 
weight loss is the marker of HIV disease progression. Hence regular 
examination of oral cavity is important. 
             Oral hairy leukoplakia (OHL): Worldwide, prevalence of 
OHL among HIV infected individual ranges from 0 to 26 per cent  54. 
One study in south India reported OHL in 4 per cent of 594 HIV 
positive individuals 4. In our study 17% of cases had OHL. 
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                 Tuberculosis [TB] is endemic in India and is the common 
cause of death in AIDS patients. Its prevalence is reported to be 
increasing in patients with HIV infection. 
                 Mycobacterium tuberculosis was the commonest isolate 
reported in few studies from India. [74], [75], [76].  But we observed 
it as the second most common pathogen (47%) as NACO.[72] 
Pulmonary tuberculosis was observed in 16% and extra pulmonary 
tuberculosis in 31% of cases. HIV infection is a strong risk factor for 
the active tuberculosis in persons with latent M. tuberculosis infection. 
The risk of active tuberculosis in HIV seropositive persons is 14% 
over 2 years - contrasting strikingly with the estimated 10% lifetime 
risk in H IV negative persons with latent tuberculosis infection.  
                  Abdominal tuberculosis, a frequently recognized form of 
extra pulmonary tuberculosis is increasing with increasing incidence 
of HIV infection, as said in The API Medicine Update volume 17, 
2007. In our study 9% had abdominal tuberculosis. All cases had 
doughy abdomen on examination and ultra sonogram abdomen 
showed enlargement of mesenteric, peri-pancreatic, peri-portal and 
para-aortic group of  lymph nodes. These nodes were seen as 
conglomerulate mass and / or as scattered enlarged lymph nodes with 
hypo echoic center because of necrosis. 
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                    Despite the prevalence of pulmonary and extra pulmonary 
TB in Indian patients, TB meningitis is less common than 
cryptococcal meningitis. In our study 6% of cases had tuberculous 
meningitis. 
          The key therapeutic principles underlying the treatment of                       
                     HIV-TB are:  
1. The treatment of TB should precede the treatment of 
HIV infection, i.e. HAART. 
2. Patients already on HAART should continue the same 
treatment with appropriate modifications, in HAART 
and ATT. 
3. Patients who are not receiving HAART, the need and 
the time of initiation of HAART have to be decided on 
individual basis after assessing the CD4 count and 
type of TB.                                                                                                
Treatment guidelines for HIV-infected patients are identical to the 
standard regimens recommended for those without HIV with two 
exceptions. Directly observed therapy [DOT] is the standard of care. 
DOTS should be initiated with isoniazid, rifampicin, ethambutol and 
pyrazinamide [HREZ] for first two months followed by isoniazid and 
rifampicin for subsequent 7 months. First exception is that treatment 
regimen should be daily or thrice a week during the continuation 
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phase. Second is that continuation phase should be extended to seven 
months. All therapeutic combinations should include a rifamycin 
(rifampicin or rifabutin) and patients should be monitored for drug 
interactions with protease inhibitors. Patients with risk factors for 
drug-resistant M tuberculosis infection may need treatment with three 
or more drugs. 
               Herpes zoster can occur early in the course of HIV disease 
and generally precedes other skin manifestations of HIV disease. In 
patients with 
HIV, it can present with necrotizing ulcers in a multidermatomal 
pattern, can last longer than the usual 2-3 wk, and heal leaving 
prominent scars. There was no associated increase in mortality  
               1% in our study group showed Herpes zoster infection, the 
incidence is low probably since it occurs in early stage of the disease 
and most of our patient presented with stage III or IV.  
                Papular pruritic eruption (PPE) is a unique dermatosis 
associated with advanced HIV infection, characterized by sterile 
papules, nodules or pustules with a hyperpigmented, urticarial 
appearance and pruritis. In our study 14% of cases were found to have 
chronic papular pruritic eruption.  
               Kaposi's sarcoma was not found in our study.                   
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               Most HIV infected persons are also infected with HSV-1 and 
HSV-2. Primary infection with HSV, at either the oral or genital sites, 
is often characterized by multiple lesions. In our study 10% of males 
30% of females had genital herpes. Genital herpes (14%) was the 
commonest genital lesion observed among the study participants 
followed by genital warts (1%). 
 This has similar incidence as in the study conducted by   J 
Chakravarty, H Mehta –‘ Study on Clinico-epidemiological Profile of 
HIV Patients in Eastern India’ published in JAPI • VOL. 54 • 
NOVEMBER 2006.                                
                          Several studies have found an increased prevalence of 
cervical dysplasia, a precursor lesion for cervical cancer, among HIV-
infected women (78). Several studies have documented that a higher 
prevalence of cervical dysplasia among HIV-infected women is 
associated with greater immunosuppression. In addition, HIV infection 
may adversely affect the clinical course and treatment of cervical 
dysplasia and cancer (79). In our study 1% had stage II cervical 
carcinoma. 
                        Cryptococcal meningitis is an opportunistic infection 
by the yeast C.neoformans and is the presenting manifestation of 
AIDS in about a third of these patients. It is the fourth most commonly 
recognized cause of life threatening infection among these patients. 
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Infection of the brain and meninges is the most common clinical 
manifestation of cryptococcosis and the most common cause of death 
from that disease. 
                          The incidence of Cryptococcal meningitis varies from 
place to place. The incidence of Cryptococcal meningitis among HIV 
cases in our study is 15% which is comparable to other reports 
(Ayyagiri et al [80] 5.6%, Bogaerts et al 3 19%, Rakhmanova et al 
[81] 17%, Silva Rosa et al 45.8%). 
                   Thus, the incidence of Cryptococcal meningitis has been 
found to be very high in our region and was the most common 
opportunistic pathogen isolated from CSF among all the pathogens put 
together.  
                   The most common ophthalmic opportunistic infection in 
India is CMV retinitis, which almost always occurs in patients with 
CD4 counts    <50 Cells/L.  
                   The second most common ophthalmic manifestation of 
HIV infection is non-infectious retinopathy (HIV retinopathy), 
reported in 13-15 per cent of HIV patients presenting to an 
ophthalmologist. This condition, characterized by cotton wool spots, 
can be an early sign of HIV infection, and must be differentiated from 
diabetic and hypertensive retinopathy.                             In our study 
CMV retinitis was 1% and HIV retinopathy was 2%. 
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                     Toxoplasmic encephalitis (TE) is caused by the 
protozoan Toxoplasma gondii. Disease occurs almost exclusively 
because of reactivation of latent tissue cysts. In our study one case had 
Toxoplasma encephalitis.  
                   One among the study participants had Neurocysticercosis.  
                   Strictly speaking, wasting syndrome is not an 
opportunistic infection.  In our study 91% of cases had wasting 
syndrome.     
                   Wasting in AIDS is now thought to be, in part, a catabolic 
process that preferentially degrades muscle mass (82). Thus, in 
addition to previously available therapies designed to boost appetite 
and caloric intake (e.g. dronabinol and megestrol acetate), anabolic 
steroids such as oxandrolone, testosterone replacement, and 
recombinant human growth hormone (83 are now given in an attempt 
to reverse this chronic breakdown state. Together with more 
aggressive antiretroviral regimens and an increased understanding of 
the nutritional requirements of patients with advanced AIDS (84), 
these new drugs have improved the ability to halt and reverse the 
previously inexorable loss of lean body mass.  
                         In our study, only 1 patient was positive for HbsAg, 
which is in contrast to Western data quoting 90- 95% incidence [85]; 
this is probably because of the fact that most of the infections take 
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place via heterosexual contact and not through infected needles and 
blood transfusion. 
             Oral hairy leukoplakia (OHL): Worldwide, prevalence of 
OHL among HIV infected individual ranges from 0 to 26 percent [86]. 
One study in south India reported OHL in 4 per cent of 594 HIV 
positive individuals[87]. In our study 17% of cases had OHL. 
                             HIV infection and psychiatric disorders have a 
complex relationship. Being HIV infected could result in psychiatric 
disorders as a psychological consequence of the infection or because 
of the effect of the HIV virus on the brain. In our study one case 
presented as schizophrenia which probably be a primary psychiatric 
illness and another as pseudo dementia.  
BLACK NAILS:  
                    Black discolouration of the nails was found in 36% of the 
cases. It is the new clinical finding noted in the study group. It is said 
that  black discolouration of the nails aiso occurs as a side effect of 
anti-retro viral therapy, but those who wer on anti-retro viral therapy 
were not included in our study. 
OTHER OBSERVATIONS 
                     Hyper pigmentation of the tongue, skin or palms was 
noted in 13% of cases. 
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                        Most cases were noted to be having normochromic 
normocytic anaemia and Liver function test showed reversal of 
albumin globulin ratio. Most of the cases, 91% presented with features 
of III or IV stage of the disease and were seriously ill. 
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CONCLUSION 
 
 
The most common age group infected was in the range of 30 -39 
years. 
Most of the cases were aware of their HIV positivity status only after 
admission in the hospital for their illness. 
Heterosexual contact was the commonest mode of transmission. 
Patients presented with more than one symptom, the common being 
fatigue, loss of weight, loss of appetite, fever and chronic cough. 
Patient had multisystem involvement. 91% of patients had developed 
AIDS related cachexia also known as ‘wasting syndrome’. 
Oral candidiasis was the commonest opportunistic infection 
followed by tuberculosis. 
Presence of oral candidiasis and weight loss can be considered as a 
marker of HIV disease progression.  
Most common genital lesion was due to Herpes simplex virus. 
Common haematological abnormality observed was anaemia. 
The incidence of Cryptococcal meningitis has been found to be very 
high in our region and  Cryptococcus neoformans was the most 
common opportunistic pathogen isolated from CSF among all the 
pathogens put together.  
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Cryptococcal infection should be suspected in all cases of meningitis 
among HIV infected persons. It most commonly develops over several 
weeks with insidious onset of headache, malaise, and fever. Early 
diagnosis and treatment may alter the prognosis for these patients.  
Extra pulmonary tuberculosis was more common than pulmonary 
tuberculosis whereas tuberculous meningitis was less frequent than 
cryptococcal meningitis. 
Only one case was Hepatitis B antigen positive. 
Chronic Papular pruritic eruption (PPE) was found in many cases             
Kaposi's sarcoma was not found in our study.  
Black discolouration of the nails was the new clinical finding in the 
study group.  
Early diagnosis of opportunistic infection and prompt treatment not 
only helps HIV-positive people to live longer, healthier lives, delaying 
the progression towards AIDS but also prevent TB and other 
transmissible  opportunistic infections from spreading to others. 
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PROFORMA 
 
                                                                       
        COIMBATORE MEDICAL COLLEGE & HOSPITAL 
A STUDY OF 100 CASES OF HIV 
MEDICAL UNIT V 
 
 
Name of the patient:                                                    Gender: M/F 
Age :                                                                            I.P.No.: 
Name of the spouse:                                                  STD No.: 
Marital of the patient:                                         Date of admission: 
Single/Married/Separated/Widow/Widower 
Address :                                                Spouse reactive for HIV I&II 
                                                                                     Yes/No 
Occupation:                                              Education: 
Income:                            
When the patient knows that he/she is HIV positive: 
Complaints : 
 
H/o present illness: 
Symptoms  Duration  Symptoms  Duration  Symptoms  Duration  
Fever  Head ache   Oral ulcer   
Cough  Appetite 
loss 
 Painful 
swallowing 
 
Sputum  Weight loss  Skin lesion   
Breathlessness  Tiredness  Loose 
stools 
 
Chest pain  Nausea/vo
miting 
 Genital 
ulcer 
 
hemoptysis  Visual 
disturbance 
 Anal ulcer  
 
Other illness 
                                                                       
H/O Past illness: 
Risk factor for acquiring infection: Sexual –PMC/EMC/Marital 
IVDrug abuse/blood transfusion/needle prick/vertical transmission. 
Family history: 
Clinical features: 
Fever  Wasting  
Pallor  Pulse rate   
Dyspnoeic  BP  
Cyanosis  Weight  in Kg  
Icterus  Black nail  
Clubbing  Pedal edema  
Skin-Seborrhoeic dermatitis/mucocutaneous herpes simplex /herpes 
zoster/ Kaposis sarcoma/molluscum contagiosum/scabies/fungal skin 
infection 
Mouth - Oral candidiasis/ Oral leukoplakia/ Glossitis/chelitis 
Lymphadenopathy: 
Ano genital : Rash/ condyloma/ mucocutaneous herpes simplex/STD 
Cardiovascular System: 
Respiratory System: 
Abdomen : 
Central Nervous System: 
                                                                       
                                INVESTIGATIONS 
Urine -albumin                                              ELISA for HIV I & II       
            Sugar                                                 VDRL 
           Deposit    
Urine Culture                                                Blood culture                                                
Motion ova/cyst                                    
Motion C/S                                                  Sputum for AFB staining                              
Complete Hemogram: 
     Hbgm%                                            
     TC cells/mm³                                           Sputum  culture    
     Dc                                                           Sputum for fungal culture            
     ESR mm/hr                                             HbsAg 
     Platelets  cells/mm³                                 HCV Ab 
    Pathologist opinion 
    Peripheral smear for MP/MF                   Blood Widal 
Blood   sugar  
Blood  Urea                                    USG abdomen     
            Sr. creatinine                                                                                 
Sr. electrolytes  
             Na+ meq/L 
             K+ meq/L                                CT                                          
LFT   
   SGOT   IU/L                                         CSF analysis 
               SGPT  IU/L      
 
                                                           Pleural Fluid Analysis 
                                                                       
             SAP  IU/L                                                            
Sr. Bilirubin   mg%                              
             Sr. proteins Total gm% 
                   Albumin gm%                        CD4 Cell count   
                  Globulin   gm%                                               
ECG:   
                                                                                                                              
X-ray chest:                                                          
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
                                                                       
ABBREVIATIONS used in master chart 
 
M-Male 
F- Female 
m- Married 
unm-unmarried 
S-Separated 
W-widow 
R-Reactive 
NR-Non reactive 
NK-not known 
L-Labourer 
DA-Diploma Agri 
y-Years 
Mn-Month 
d-Day 
Visual disturbance- blurring of vision, double vision  
CNS symptoms- disorientation, fits, difficulty in using limbs 
Seborrhoeic dermatitis 
KS-Kaposi’s sarcoma 
OC-Oral candidiasis 
CPPD-Chronic pruritic papular dermatitis 
OLP- Oral hairy leukoplakia 
B/L C- B/L Cervical lymphadenopathy 
B/L C, A-  B/L Cervical, Axillary lymphadenopathy 
Cold A- Cold abscess 
Retina- P-Papilloedema, CMVR- CMV retinopathy, HIVR- HIV retinitis 
N-Normal 
CVS-Cardiovascular system 
RS-Respiratory system- B-Right pleural effusion 
                                       C-B/L pleural effusion 
                                       D-Right lower lobe consolidation 
                                       E-Right upper lobe consolidation 
                                       F-Left upper lobe fibrosis 
                                       G-Left lower lobe consolidation 
                                       H- Right upper lobe fibrosis 
                                       I- Left pleural effusion 
                                       J-Right pyothorax 
                                       K-B/L Wheeze, crepts   
Abdomen- O-Doughy, O,1-Doughy, Para aortic node felt 
                                      Oa-mutiple para aortic nodes 
                                      O,2- Doughy, right iliac fossa mass  
                                      4- Hepatosplenomegaly 
                                      4a-hepatomegaly 
                                      4b-splenomegaly 
                                      4c- multiple enlarged lymph nodes-   
                                         portahepatis, coeliac, paraaortic both iliac 
                                         suggestive of  tuberculosis of abdomen 
                                    4d- grade 1 fatty liver 
                                    4e- ascending colon thickening 
 
                                                                       
  
                                      3-Ascites,   
                                Cx- endocervix irregularly thickened-12mm uterus bulky 
 
CNS-Central nervous system  
5- Right upper motor neuron facial palsy, right upper limb weakness 
6-Neck stiffness 
7-Right sided weakness 
8-GTCS 
9- Pseudo-dementia, patchy memory lapses 
10- Left hemi paresis 
11- Schizophrenia 
12- Proximal muscle weakness, muscle wasting 
13-Neck stiffness, cranial nerve palsy , right hemiparesis 
Urine culture: a- proteus group grown 
                       b- Escherichia coli grown culture 
                       c- Klebsiella pneumonia grown culture 
NFG- Normal flora grown 
Pathologist opinion- d- Dimorphic anaemia 
                                  e- microcytic hypo chromic anaemia 
                                  f- marked neutrophilic leucocytosis 
                                  g- normocytic to microcytic anaemia  
                                  h- normochromic normocytic anaemia 
                                  r- Relative neutrphilia 
Blood WIDAL –j- O&H +1 in 100 dilution 
X-RAY chest- Q- thick walled cavity left mid zone 
                        T- B/T Pulmonary tuberculosis 
                         U- upper mediastinal Widening 
ECG- ST-sinus tachycardia 
CSF- NO- No bacteria 
Urine culture 
                         Ac- acinetobacter grown 
 
                               S.p- S.pyogenes 
                         K.p- Klebsiella pneumonia 
                          c.neg.S.- coagulase negative Staphlococcus 
                          Str.- Streptococcus  
                         E.c-E coli  
                         Pr-  Proteus group grown 
                         Asp-  Aspergillus niger grown 
                         Ps.- Pseudomonas 
                         C.a - Candida  
 
CT-brain 
                   c1-multiple abscess in brain 
                   c2- infarct in left parieto occipital cortex 
                   c3- chronic SDH 
                   c4- right frontal, parietal region ring enhancing multiple lesion 
                                                                       
                   c5- ring enhancing lesion with perilesional edema in right  
                         parietal region 
                   c6- atrophic change 
                   c7- left frontal ring enhancing lesion with perilesional edema 
                   c8- gliosis  
                    
CSF analysis 
                   c9- 0 to 15 yeast cells 
                        Lc- lymphocytes  
                        ce- cells 
                        s- sugar 
                        p- protein 
                        g- globulin 
                        cl- chloride 
 
Pleural fluid analysis  
                        P1- 2000pus cells, S.pyogenes grown, protein4.8, albumin1.9 
                   LDH- Lactate dehydrogenase 
 
 
 
 
 
